argenx NV ADR (ARGX)vsMereo BioPharma Group PLC ADR (MREO)
ARGX
argenx NV ADR
$872.58
-1.13%
HEALTHCARE · Cap: $54.24B
MREO
Mereo BioPharma Group PLC ADR
$0.31
-0.94%
HEALTHCARE · Cap: $48.22M
Smart Verdict
WallStSmart Research — data-driven comparison
argenx NV ADR generates 1062994% more annual revenue ($5.32B vs $500,000). ARGX leads profitability with a 32.3% profit margin vs 0.0%. ARGX earns a higher WallStSmart Score of 73/100 (B).
ARGX
Strong Buy73
out of 100
Grade: B
MREO
Avoid25
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+65.6%
Fair Value
$2427.69
Current Price
$872.58
$1555.11 discount
Intrinsic value data unavailable for MREO.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 31 in profit
Keeps 32 of every $100 in revenue as profit
Strong operational efficiency at 32.0%
Revenue surging 59.3% year-over-year
Earnings expanding 95.2% YoY
Conservative balance sheet, low leverage
Reasonable price relative to book value
Areas to Watch
Premium valuation, high expectations priced in
Weak financial health signals
Trading at 184.5x book value
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : ARGX
The strongest argument for ARGX centers on Return on Equity, Profit Margin, Operating Margin. Profitability is solid with margins at 32.3% and operating margin at 32.0%. Revenue growth of 59.3% demonstrates continued momentum.
Bull Case : MREO
The strongest argument for MREO centers on Price/Book.
Bear Case : ARGX
The primary concerns for ARGX are P/E Ratio, Piotroski F-Score, Price/Book.
Bear Case : MREO
The primary concerns for MREO are Revenue Growth, EPS Growth, Market Cap.
Key Dynamics to Monitor
ARGX profiles as a growth stock while MREO is a value play — different risk/reward profiles.
MREO carries more volatility with a beta of 0.29 — expect wider price swings.
ARGX is growing revenue faster at 59.3% — sustainability is the question.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
ARGX scores higher overall (73/100 vs 25/100), backed by strong 32.3% margins and 59.3% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
argenx NV ADR
HEALTHCARE · BIOTECHNOLOGY · USA
argenx SE, a clinical-phase biotechnology company, focuses on the development of antibody-based therapies for the treatment of autoimmune diseases, hematology and cancer. The company is headquartered in Breda, the Netherlands.
Mereo BioPharma Group PLC ADR
HEALTHCARE · BIOTECHNOLOGY · USA
Mereo BioPharma Group plc, a biopharmaceutical company, acquires, develops and markets therapeutic products for the treatment of oncology and rare diseases in the UK and internationally. The company is headquartered in London, the United Kingdom.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?